Vol. 1 No. 12 (2021)
Reimbursement Recommendations

Luspatercept (Reblozyl)

Published December 23, 2021

Key Messages

  • CADTH recommends that Reblozyl should be reimbursed by public drug plans for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, if certain conditions are met.
  • Reblozyl should only be covered to treat patients who have failed or are not suitable for erythropoietin-based therapy.
  • Reblozyl should only be reimbursed if prescribed by a specialist in MDS and if the cost of Reblozyl is reduced. Reimbursement should only be renewed if Reblozyl shows benefit to the patient such that the patient no longer requires RBC transfusions.